Insulet
PODD
578 hedge funds and large institutions have $20.7B invested in Insulet in 2023 Q2 according to their latest regulatory filings, with 70 funds opening new positions, 216 increasing their positions, 206 reducing their positions, and 70 closing their positions.
5% more repeat investments, than reductions
Existing positions increased: 216 | Existing positions reduced: 206
0% more funds holding in top 10
Funds holding in top 10: 9 → 9 (0)
0% more first-time investments, than exits
New positions opened: 70 | Existing positions closed: 70
1% less funds holding
Funds holding: 582 → 578 (-4)
1.92% less ownership
Funds ownership: 104.85% → 102.93% (-1.9%)
11% less capital invested
Capital invested by funds: $23.3B → $20.7B (-$2.61B)
29% less call options, than puts
Call options by funds: $58.4M | Put options by funds: $82.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCP
D1 Capital Partners
New York
|
+$85.4M |
| 2 |
Man Group
London,
United Kingdom
|
+$84.3M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$76.9M |
| 4 |
BlackRock
New York
|
+$72.9M |
| 5 |
JP Morgan Chase
New York
|
+$71.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$356M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$211M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
-$119M |
| 4 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$100M |
| 5 |
Jane Street
New York
|
-$71M |
PODD Hedge Fund Activity: Q2 2023 in Review
578 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Insulet (PODD) for Q2 2023, worth a combined $20.7B — down 11% from $23.3B a quarter earlier.
Fund positioning in PODD was balanced in Q2 2023: 70 funds opened new positions, 70 closed out, 216 added to existing stakes and 206 trimmed.
The largest buyer was D1 Capital Partners, adding an estimated $85.4M. The largest seller was T. Rowe Price Associates, cutting an estimated $356M.
- 578 institutional investors held Insulet (PODD) as of Q2 2023, down from 582 in Q1 2023.
- Funds reported $20.7B of Insulet stock for Q2 2023, down 11% quarter-over-quarter.
- 70 funds opened new Insulet positions in Q2 2023 and 70 closed out, a net change of 0 holders.
- The largest Insulet buyer in Q2 2023 was D1 Capital Partners, an estimated $85.4M added.
- The largest Insulet seller in Q2 2023 was T. Rowe Price Associates, an estimated $356M sold.
Based on aggregated 13F filings for Q2 2023.